LITS
Lite Strategy, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.16
+0.87%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +27.3%
- EBIT
- +26.7%
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -47.6%
Three-year CAGR
- Revenue
- —
- EBITDA
- +28.2%
- EBIT
- +29.7%
- Net income
- —
- EPS
- +13.8%
- Free cash flow
- +56.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026